Today: 29 June 2026
Browse Category

NASDAQ:IBRX 29 November 2025 - 18 January 2026

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

ImmunityBio shares soared 40% to $5.52 Friday after the company reported preliminary 2025 net product revenue of $113 million and new approvals for ANKTIVA in Saudi Arabia. Trading volume topped 182 million shares. Enrollment in its key bladder cancer trial is over 85% complete, with FDA submission targeted by late 2026. Early data from its CAR-NK cell therapy showed complete remission in two Waldenström lymphoma patients.
18 January 2026
··
ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio shares surged 39.8% to $5.52 Friday after the company projected 2025 ANKTIVA net product revenue of $113 million, up about 700% from last year. The stock rose further to $6.04 in after-hours trading. Trial enrollment for its bladder cancer study reached over 85%, and new CAR-NK data showed a 15-month complete response in Waldenström lymphoma.
18 January 2026
·
ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio shares jumped 39.9% to $5.52 Friday after reporting a sharp rise in preliminary 2025 ANKTIVA sales and positive trial updates. The company projected about $113 million in 2025 net product revenue for ANKTIVA, up nearly 700% from 2024. An interim analysis showed higher complete response rates for ANKTIVA plus BCG in bladder cancer. U.S. markets reopen Tuesday after the MLK Jr. holiday.
17 January 2026
·
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares surged 35% Friday after reporting faster enrollment and positive interim results in its ANKTIVA bladder cancer trial. The company also disclosed $113 million in 2025 preliminary revenue and Saudi approval for ANKTIVA in lung cancer. Shares traded at $5.34 by midday with 133 million shares changing hands. Early data from its CD19 CAR-NK cell therapy showed complete responses in Waldenström lymphoma.
16 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio shares rose 6.4% to $2.76 Tuesday after reporting new lung cancer trial data for its drug ANKTIVA. The company said ANKTIVA combined with checkpoint inhibitors restored immune-cell levels in two studies, with one showing longer median survival for patients with higher lymphocyte counts. A Phase 3 trial comparing ANKTIVA to docetaxel is ongoing. Fuller results are pending peer review.
13 January 2026
··
ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

The European Medicines Agency’s CHMP issued a positive opinion recommending conditional marketing authorization for ImmunityBio’s Anktiva plus BCG in BCG-unresponsive non-muscle invasive bladder cancer. IBRX shares closed at $2.36 on Dec. 12, up 7.76% on heavy volume, and traded near $2.39 pre-market Dec. 15. The European Commission has not yet given final approval.
15 December 2025
··
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio shares surged up to 13% on November 28 after reporting Q3 revenue of $32.1 million, up from $6.1 million a year earlier, driven by Anktiva sales. The company posted a Q3 net loss of $67.3 million and a nine-month cash outflow of $234.6 million. Anktiva is FDA-approved for certain bladder cancer patients in the U.S. and recently gained UK approval. Shares remain down mid-teens for the year.
29 November 2025
···
1 2

Stock Market Today

  • 3 ASX Dividend Stocks Yielding Up To 4.7% Amid Market Volatility
    June 28, 2026, 6:06 PM EDT. As Australian stocks show resilience, investors focus on dividend stocks offering steady income in uncertain markets. Australian Ethical Investment Ltd (ASX:AEF) yields 3.4%, backed by earnings coverage but with past dividend volatility. Ricegrowers Limited (ASX:SGLLV) provides a 4.4% yield, supported by recent earnings growth and a sustainable payout ratio. The report highlights dividend investors' appeal amid geopolitical tensions and market fluctuations, with yields up to 4.7% offering an attractive balance of income and risk.

Latest articles

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
AMD stock trades short week over Street average after chip selloff

AMD stock trades short week over Street average after chip selloff

28 June 2026
AMD closed Friday down 2.06% at $521.58—still 3.6% above the average analyst target of $502.92—after heavy volume and a weeklong chip sector selloff, leaving investors with little margin for error as the stock outpaces Wall Street expectations ahead of the July 3 market holiday.
Tesla slips again heading into delivery mix test; TSLA energy gap now wider

Tesla slips again heading into delivery mix test; TSLA energy gap now wider

28 June 2026
Tesla closed at $379.71, up 1.22% Friday but down 5.2% for the week, as Q2 delivery consensus shows a 1.1% gain to 406,024 vehicles—driven solely by Model 3/Y—while “all other models” decline, raising questions about Tesla’s $1.43 trillion valuation with 2026 vehicle growth nearly flat versus 2025.
ACHR stock: Archer Aviation Texas proposal falls short after strong support

ACHR stock: Archer Aviation Texas proposal falls short after strong support

28 June 2026
Archer Aviation (NYSE:ACHR) failed to secure enough shareholder votes for its Texas redomestication plan despite over 80% support from shares voted, keeping its annual $250,000 Delaware tax bill and leaving the stock near a 52-week low, with short interest at 19.43% of float and a five-day loss of 10.31%.
Go toTop